Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Update

Alzamend Neuro, Inc. (NASDAQ:ALZNGet Rating) was the target of a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 1,170,000 shares, an increase of 17.2% from the June 30th total of 998,700 shares. Currently, 4.0% of the company’s stock are short sold. Based on an average trading volume of 499,300 shares, the short-interest ratio is currently 2.3 days.

Alzamend Neuro Stock Performance

Shares of NASDAQ:ALZN opened at $0.90 on Wednesday. The business has a 50 day moving average price of $0.91 and a 200 day moving average price of $1.08. Alzamend Neuro has a twelve month low of $0.80 and a twelve month high of $4.84.

Insider Activity

In related news, major shareholder Milton C. Ault III acquired 100,000 shares of the stock in a transaction dated Thursday, May 5th. The shares were acquired at an average price of $1.07 per share, with a total value of $107,000.00. Following the acquisition, the insider now owns 325,000 shares in the company, valued at approximately $347,750. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders have purchased 233,000 shares of company stock valued at $227,613.

Institutional Trading of Alzamend Neuro

Several hedge funds have recently added to or reduced their stakes in ALZN. Truist Financial Corp bought a new stake in Alzamend Neuro during the 1st quarter valued at approximately $2,847,000. RFG Advisory LLC bought a new stake in shares of Alzamend Neuro in the 1st quarter worth approximately $308,000. Commonwealth Equity Services LLC bought a new stake in shares of Alzamend Neuro in the 4th quarter worth approximately $221,000. Qube Research & Technologies Ltd bought a new stake in shares of Alzamend Neuro in the 1st quarter worth approximately $97,000. Finally, Bank of America Corp DE bought a new stake in shares of Alzamend Neuro in the 1st quarter worth approximately $35,000. Institutional investors own 0.95% of the company’s stock.

About Alzamend Neuro

(Get Rating)

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative diseases and psychiatric disorders. Its pipeline includes AL001, an ionic cocrystal technology delivering a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's and other neurodegenerative diseases, and psychiatric disorders; and AL002, a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's.

Further Reading

Receive News & Ratings for Alzamend Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alzamend Neuro and related companies with MarketBeat.com's FREE daily email newsletter.